We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Six Hundredth Heart Attack Patient Recruited Into Phase III CicloMulsion CIRCUS Trial
Six Hundredth Heart Attack Patient Recruited Into Phase III CicloMulsion CIRCUS Trial
March 22, 2013
NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heartreperfusion injury following stenting in patients with myocardial infarction. Yahoo! News
